Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) (“Nurix”) on behalf of the company’s investors.
Since July 2023, shares of Nurix’s common stock have declined in value from a trading price of over $10.00 per share to a current trading price of less than $5.50 per share, a cumulative decline of 45% in value.
The investigation seeks to determine whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.
Nurix stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.